Kaneka Eurogentec, an affiliate of Japan’s Kaneka based at Liège, Belgium, has signed an agreement to make the INO-4800 DNA vaccine candidate for COVID-19 for Inovio Pharmaceuticals, a US biotech, at commercial scale in its GMP facility. Financial terms were not disclosed.

INO-4800 uses plasmid DNA as a drug substance and has just received US FDA clearance to move to the second part of its Phase II-III clinical trials. These trials have financial support from the US Department of Defense.